台股 » 個股 » 國光生 » 籌碼相關 » 券商分點績效

國光生

(4142)
可現股當沖
  • 股價
    26.50
  • 漲跌
    ▼0.20
  • 漲幅
    -0.75%
  • 成交量
    407
  • 產業
    上市 生技醫療類股
  • 633人加入追蹤

    立即追蹤

  • 本地時間:13:35(已收盤)

     
國光生 (4142)籌碼相關-券商分點績效/獲利分析
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

«前一日     2024/03/28     後一日»

券商獲利排行 - 2024/03/28

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  0.54%1.90.21.71213126.626.626.826.7
  0.66%1.801.81010026.526.5026.7
  0.38%1.501.51515026.626.6026.7
  0.39%1.101.11011026.626.626.826.7
  0.75%10155026.526.5026.7
  0.75%10155026.526.5026.7
  0.42%0.900.988026.626.6026.7
  0.53%0.700.755026.626.6026.7
  0.66%0.70.10.634126.526.526.626.7
  0.61%0.70.20.434126.626.626.826.7
  0.75%0.600.633026.526.5026.7
  0.75%0.600.633026.526.5026.7
  0.56%0.600.644026.626.6026.7
  0.56%0.60.30.324226.626.626.726.7
  0.41%0.600.655026.626.6026.7
  0.52%0.60.20.334126.626.626.826.7
  0.38%0.500.555026.626.6026.7
  0.38%0.500.555026.626.6026.7
  0.56%0.500.533026.626.6026.7
  0.38%0.400.444026.626.6026.7
  0.75%0.400.422026.526.5026.7
  0.15%0.40.40-731026.726.626.726.7
  0.75%0.400.422026.526.5026.7
  0.75%0.400.422026.526.5026.7
  0.75%0.400.412026.526.526.826.7
  0.12%0.400.41111026.726.7026.7
  0.44%0.400.433026.626.6026.7
  0.38%0.300.333026.626.6026.7
  0.38%0.300.333026.626.6026.7
  0.38%0.300.323126.626.626.626.7
  0.56%0.300.322026.626.6026.7
  0.56%0.300.322026.626.6026.7
  0.56%0.300.322026.626.6026.7
  1.13%0.30.3001126.726.526.826.7
  0.38%0.300.333026.626.6026.7
  0.19%0.300.355026.726.7026.7
  0.47%0.30.10.112126.726.626.826.7
  0.47%0.20.10.112126.626.626.726.7
  0.25%0.200.233026.626.6026.7
  0.38%0.200.222026.626.6026.7
  0.38%0.200.222026.626.6026.7
  0.75%0.200.211026.526.5026.7
  0.75%0.200.211026.526.5026.7
  0.75%0.200.211026.526.5026.7
  0.75%0.200.211026.526.5026.7
  0.75%0.200.211026.526.5026.7
  0.75%0.200.211026.526.5026.7
  0.75%0.200.211026.526.5026.7
  0.75%0.200.211026.526.5026.7
  0.75%0.200.211026.526.5026.7

券商虧損排行 - 2024/03/28

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  -0.58%-4.2-3.6-0.6-2242726.626.626.526.7
  -0.25%-3.40.3-3.6-4825026.626.526.626.7
  -0.34%-3.2-0.9-2.3-21143526.626.726.626.7
  -0.59%-2.70-2.7-1701726.5026.526.7
  -0.79%-2.1-0.5-1.6-821026.526.826.526.7
  -0.56%-1.50-1.5-1001026.6026.626.7
  -0.24%-1.4-1.80.34231926.626.626.526.7
  -0.56%-1.20-1.2-80826.6026.626.7
  -0.54%-1.20-1.2-80826.6026.626.7
  -0.38%-1.10-1.1-1101126.6026.626.7
  -0.56%-1.1-0.2-0.9-61726.626.826.626.7
  -0.75%-10-1-50526.5026.526.7
  -0.09%-0.8-0.1-0.7-3123326.726.726.726.7
  -0.56%-0.80-0.8-50526.6026.626.7
  -0.56%-0.7-0.7005526.626.726.526.7
  -0.13%-0.60-0.6-1601726.726.826.726.7
  -0.56%-0.50-0.5-30326.6026.626.7
  -0.75%-0.40-0.4-20226.5026.526.7
  -0.50%-0.4-0.3-0.1-12326.726.826.626.7
  -0.56%-0.30-0.3-20226.6026.626.7
  -0.37%-0.30-0.333026.826.8026.7
  -0.19%-0.30-0.3-50526.7026.726.7
  -0.31%-0.30-0.3-30326.6026.626.7
  -0.38%-0.20-0.2-20226.6026.626.7
  -0.75%-0.2-0.2001126.626.726.526.7
  -0.19%-0.20-0.244026.826.8026.7
  -0.19%-0.2-0.1-0.1-21326.726.726.726.7
  -0.56%-0.20-0.2-10126.6026.626.7
  -0.56%-0.20-0.2-10126.6026.626.7
  -0.56%-0.20-0.2-10126.6026.626.7
  -0.56%-0.20-0.2-10126.6026.626.7
  -0.19%-0.10-0.1-20226.7026.726.7
  -0.38%-0.10-0.1-10126.6026.626.7
  -0.38%-0.10-0.1-10126.6026.626.7
  -0.38%-0.10-0.1-10126.6026.626.7
  -0.38%-0.10-0.1-10126.6026.626.7
  -0.38%-0.1-0.1001126.626.626.526.7
  -0.38%-0.1-0.1001126.626.626.526.7
  -0.13%-0.1-0.1003326.626.626.626.7
  -0.37%-0.10-0.111026.826.8026.7
  -0.12%-0.10-0.133026.726.7026.7
  -0.07%-0.1-0.1005426.726.726.626.7
  -0.09%-0.10-0.1-20226.7026.726.7
  -0.19%-0.10-0.1-10126.7026.726.7
  -0.19%-0.10-0.1-10126.7026.726.7
  -0.19%-0.10-0.1-10126.7026.726.7
  -0.19%-0.1-0.1001126.726.826.726.7
  -0.19%00011026.826.8026.7
  -0.19%00011026.826.8026.7
  -0.19%00011026.826.8026.7
國光生去年營運轉虧 今年拚重回成長軌道Anue鉅亨-15天前
〈國光生展望〉子公司安特羅腸病毒三期臨床入尾聲 明年展開IPOAnue鉅亨-2023/12/26
〈國光生展望〉流感疫苗申請巴西藥證+破傷風切新市場 外銷業績拚成長Anue鉅亨-2023/12/26
國光生 相關文章